{"entity":{"id":"hyperphosphataemia-on-fgfr-inhibitors","kind":"protocol","name":"High phosphate on FGFR inhibitors (erdafitinib, pemigatinib, futibatinib): monitoring, diet, binders and dose rules","aka":["erdafitinib hyperphosphataemia","pemigatinib hyperphosphataemia","futibatinib hyperphosphataemia","FGFR inhibitor hyperphosphatemia","high phosphate on Balversa","high phosphate on Pemazyre","high phosphate on Lytgobi","low phosphate diet on FGFR inhibitors","phosphate binders with FGFR inhibitors"],"tldr":"Erdafitinib, pemigatinib and futibatinib raise blood phosphate in most people, usually in the first weeks. Phosphate is checked with blood tests. A rise is treated with a low-phosphate diet, tablets taken with food that bind phosphate, and sometimes a pause or a lower dose. Report cramps, tingling round the mouth or painful skin lumps. Your own team's plan comes first.","summary":"FGFR1 signalling in the proximal tubule, driven by FGF23, limits phosphate reabsorption; blocking it raises serum phosphate. It is an expected pharmacodynamic effect: the US labels report raised phosphate in 73% of patients on erdafitinib (median onset 16 days), 93% on pemigatinib (8 days) and 88% on futibatinib (5 days), with phosphate binders used in 24% and 77% on erdafitinib and futibatinib and phosphate-lowering therapy in 33% on pemigatinib. Prolonged hyperphosphataemia can cause soft tissue mineralisation, cutaneous calcinosis, non-uraemic calciphylaxis and vascular calcification.\n\nThe three labels set different thresholds. Diet: erdafitinib restricts phosphate to 600 to 800 mg a day in everyone (US) or from 5.5 mg/dL, 1.75 mmol/L (EU); pemigatinib starts a low-phosphate diet above 5.5 mg/dL; futibatinib starts diet and a binder at 5.5 mg/dL or more. Binder: erdafitinib from 7 mg/dL (2.25 mmol/L) and pemigatinib above 7 mg/dL (both labels say phosphate-lowering therapy or a binder is started in their dose tables, and \"consider\" or \"should be considered\" in the erdafitinib warnings and the EU pemigatinib text). Dose: erdafitinib continues at 7 to 8.99 mg/dL, is withheld at 9 to 10 mg/dL (2.91 to 3.20 mmol/L) and restarted at the same dose, may be restarted one level lower after a value above 10 mg/dL, and is stopped for good if 10 mg/dL or more lasts over 2 weeks. Pemigatinib is continued while phosphate-lowering therapy is started, and withheld if phosphate is not under 7 mg/dL within 2 weeks of starting it or, when above 10 mg/dL, not 10 mg/dL or less within 1 week. Futibatinib is reduced, not withheld, above 7 mg/dL, and withheld above 10 mg/dL. Erdafitinib is also the only one whose dose is raised (8 to 9 mg) if phosphate is under 9.0 mg/dL at 14 to 21 days.\n\nChoice of binder is opinion: the EU erdafitinib text suggests a non-calcium binder such as sevelamer; an unfunded review (Kommalapati 2021) prefers lanthanum or calcium-based binders when there is diarrhoea and says acetazolamide can be considered after the binder dose has been raised; an Incyte-sponsored review (Subbiah 2023) says calcium carbonate may be used unless calcium is raised, when sevelamer is preferred. All three EU texts warn of hypophosphataemia: the futibatinib text says binders and diet should be discontinued if treatment stops or phosphate falls below normal, the pemigatinib text says this should be considered during treatment breaks or if phosphate falls below normal, and the erdafitinib text says to discontinue them if phosphate falls below normal. No independent guideline was found.","asOf":"2026-11-17","links":[],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["fgfr1","fgfr2"],"drugs":["erdafitinib","pemigatinib","futibatinib"],"companies":[],"institutions":[],"pathways":["fgfr-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"These cancer tablets make a salt called phosphate build up in the blood. Your team checks it with blood tests. If it is high you may be asked to eat less of some foods, take a tablet with meals that soaks up phosphate, or stop the cancer tablets for a while. Tell your team about muscle cramps, tingling round the mouth or sore lumps in the skin.","domain":"symptom-management","setting":{"who":["doctor","nurse","pharmacist","patient-or-carer"],"where":["outpatient-clinic","home","telephone-triage"]},"population":"Adults taking erdafitinib (urothelial cancer with an FGFR3 alteration), pemigatinib (cholangiocarcinoma with an FGFR2 fusion or rearrangement; myeloid or lymphoid neoplasms with FGFR1 rearrangement) or futibatinib (intrahepatic cholangiocarcinoma with an FGFR2 fusion or rearrangement). Infigratinib and FGFR inhibitors in trials are not covered. The rules here are the labels' rules for adults in general; the EU erdafitinib text adds stopping the drug for a significant change in kidney function or grade 3 hypocalcaemia due to hyperphosphataemia. Children are not covered; the US erdafitinib label reports skeletal adverse reactions in children.","trigger":"An FGFR inhibitor is about to be started, or a blood test during treatment shows a phosphate above the normal range.","steps":[{"action":"Measure phosphate before the first dose","why":"A starting value is needed to judge later rises, and the dose rules are written around phosphate levels.","source":"smpc-balversa","quote":"Phosphate concentrations should be assessed prior to the first dose and then monitored monthly."},{"action":"Teach every patient about a low-phosphate diet, with a handout listing lower-phosphate alternatives","why":"The review says phosphate is in almost all food, with more in processed and animal foods, dairy, whole grains, lentils and nuts, so cutting it down needs specific swaps.","source":"kommalapati-2021","quote":"Patients on FGFR inhibitors should invariably be educated about dietary modifications, to reduce the risk of developing hyperphosphatemia"},{"action":"Check phosphate throughout treatment: on erdafitinib at 14 to 21 days and then monthly; on pemigatinib and futibatinib weekly once phosphate-lowering therapy has started","why":"The labels report that phosphate first rose after a median of 5 days (futibatinib), 8 days (pemigatinib) and 16 days (erdafitinib). The pemigatinib and futibatinib labels set no schedule before it is raised.","source":"label-futibatinib","quote":"Monitor for hyperphosphatemia throughout treatment."},{"action":"For erdafitinib, check phosphate at 14 to 21 days: raise the dose to 9 mg only if it is under 9.0 mg/dL (2.91 mmol/L) and there are no eye problems or other moderate side effects","why":"The label calls the rise in phosphate a pharmacodynamic effect of the drug and sets the dose by this one reading. The EU text words the second condition as no drug-related toxicity, and says phosphate should not guide a dose increase after day 21.","source":"label-erdafitinib","quote":"Increase the dose of BALVERSA to 9 mg once daily if serum phosphate level is < 9.0 mg/dL and there are no ocular disorders or Grade 2 or greater adverse reactions."},{"action":"Avoid medicines and supplements that change phosphate, especially before the first erdafitinib phosphate check, and do not start vitamin D supplements on erdafitinib without advice","why":"They can alter the phosphate reading used to set the dose, and the EU text says vitamin D may add to raised phosphate and calcium.","source":"smpc-balversa","quote":"Supplementation with vitamin D in patients receiving erdafitinib is not recommended due to potential contribution to increased serum phosphate and calcium levels."},{"action":"Start a low-phosphate diet when phosphate goes above 5.5 mg/dL (1.75 mmol/L); on erdafitinib keep to 600 to 800 mg of phosphate a day (from the start in the US label, from 5.5 mg/dL in the EU text)","why":"Each label puts diet before, or alongside, phosphate-lowering medicine. The futibatinib label starts diet at 5.5 mg/dL or more.","source":"label-pemigatinib","quote":"Monitor for hyperphosphatemia and initiate a low phosphate diet when serum phosphate level is > 5.5 mg/dL."},{"action":"Start phosphate-lowering therapy (on erdafitinib a binder taken with food) when phosphate reaches 7 mg/dL (2.25 mmol/L) on erdafitinib, goes above 7 mg/dL on pemigatinib, or reaches 5.5 mg/dL on futibatinib","why":"A binder reduces the phosphate absorbed from food. The erdafitinib dose table says to start one at 7 to 8.99 mg/dL, while its warnings section, quoted here, says to consider one above 7.0 mg/dL; the EU pemigatinib text also says \"should be considered\". The pemigatinib and futibatinib labels then check phosphate weekly.","source":"label-erdafitinib","quote":"If serum phosphate is above 7.0 mg/dL, consider adding an oral phosphate binder until serum phosphate level returns to <7.0 mg/dL."},{"action":"Choose the binder for the person: check calcium first, and take account of diarrhoea","why":"The review prefers lanthanum to calcium-based binders when calcium is already high, and says sevelamer, magnesium-based binders and sucroferric oxyhydroxide can worsen the diarrhoea these medicines cause. Sources differ on which to use first (see variants).","source":"kommalapati-2021","quote":"Similarly, lanthanum is preferred over calcium-based regimens in patients with baseline hypercalcemia and who are at high risk of vascular calcifications."},{"action":"Start the binder at the lowest possible dose and consider raising it according to the phosphate response","why":"The review says side effects and frequent dosing make binders hard to keep taking, and that low phosphate in the trials may have come from over-correction with binders. A second review gives the same advice to limit hypophosphataemia.","source":"kommalapati-2021","quote":"Hence, phosphate binders should be administered at the lowest possible dose and dose escalation should be considered based on the response and desired phosphorous levels."},{"action":"Follow the dose table for that medicine once phosphate is above 7 mg/dL: erdafitinib continues with a binder and is withheld at 9 mg/dL (2.91 mmol/L) or more until it is back under 7 mg/dL","why":"Each medicine has its own rule, and they are not interchangeable (see variants).","source":"label-erdafitinib","quote":"Withhold BALVERSA with weekly reassessments until level returns to <7 mg/dL. Then restart BALVERSA at the same dose level."},{"action":"Above 10 mg/dL (3.20 mmol/L), withhold erdafitinib or futibatinib; withhold pemigatinib if phosphate is not 10 mg/dL or less within 1 week of starting phosphate-lowering therapy. Restart at a lower dose once it is 7 mg/dL or less (futibatinib) or under 7 mg/dL (the others), and stop for good as that medicine's label specifies","why":"The labels say raised phosphate can lead to mineral deposits in soft tissue, skin and blood vessels. The quoted rule is futibatinib's; the three rules are set out under variants.","source":"label-futibatinib","quote":"Withhold LYTGOBI until phosphate is ≤7 mg/dL and resume LYTGOBI at the next lower dose."},{"action":"Tell patients to report painful skin lesions, muscle cramps, numbness or tingling round the mouth to their team immediately","why":"The labels name cramps, numbness and tingling as symptoms of an acute change in phosphate, and list skin calcinosis and non-uraemic calciphylaxis among the effects of raised phosphate. The US pemigatinib and futibatinib labels name the cramps, numbness and tingling but not skin lesions.","source":"label-erdafitinib","quote":"Advise patients to immediately inform their healthcare provider of painful skin lesions or any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth"},{"action":"Consider stopping the binder and the diet during a break from pemigatinib or if phosphate falls below normal; on futibatinib stop them if treatment stops or phosphate falls below normal, and on erdafitinib if phosphate falls below normal","why":"The EU texts warn of low phosphate, which when severe may present with confusion, seizures and muscle weakness. Only the pemigatinib text words this as something to consider.","source":"smpc-pemazyre","quote":"Discontinuing phosphate-lowering therapy and diet should be considered during Pemazyre treatment breaks or if serum phosphate level falls below normal range."},{"action":"Keep the eye checks the label requires alongside the phosphate checks: an eye examination with a retinal scan (OCT) before starting and at the stated intervals, and urgently for any change in vision","why":"The same medicines can cause retinal pigment epithelial detachment, which may blur vision; it is managed separately from phosphate. The intervals differ by medicine and between the US and EU texts.","source":"label-pemigatinib","quote":"Perform a comprehensive ophthalmological examination including OCT prior to initiation of PEMAZYRE and every 2 months for the first 6 months and every 3 months thereafter during treatment."}],"bestInClass":{"statement":"There is no independent guideline; the regulators' texts are the firmest source, and they differ by medicine and, for erdafitinib, between the US and the EU. All agree on monitoring phosphate, a low-phosphate diet, phosphate-lowering therapy once phosphate is above 7 mg/dL (2.25 mmol/L) at the latest, restarting at a lower dose after the medicine has been withheld for a value above 10 mg/dL (3.20 mmol/L), and telling patients to report cramps, numbness and tingling round the mouth immediately (the erdafitinib texts and the EU futibatinib leaflet add painful skin lesions). They differ on when diet starts (everyone on erdafitinib in the US; from 5.5 mg/dL in the EU and for pemigatinib), when a binder starts (5.5 mg/dL for futibatinib, 7 mg/dL for the others), what happens between 7 and 10 mg/dL (erdafitinib continues to 8.99 and is withheld from 9; pemigatinib continues for up to 2 weeks on phosphate-lowering therapy and is withheld if phosphate is not under 7 mg/dL by then; futibatinib is reduced by one dose level), and what happens above 10 mg/dL (erdafitinib and futibatinib are withheld; pemigatinib is withheld only if phosphate is not 10 mg/dL or less within 1 week). Weekly checks are written into the pemigatinib and futibatinib rules once therapy starts, and into the erdafitinib rule while the drug is withheld. On the choice of binder the sources disagree and none is graded: the EU erdafitinib text suggests a non-calcium binder such as sevelamer carbonate; an unfunded review prefers lanthanum or calcium-based binders in people with diarrhoea and lanthanum when calcium is high; an Incyte-sponsored review says calcium carbonate may be used unless calcium is raised, when sevelamer is preferred. All three EU texts add that binders and diet should be discontinued if phosphate falls below normal (the pemigatinib text says this should be considered); the futibatinib text says the same when treatment is stopped and the pemigatinib text during treatment breaks.","sources":["label-erdafitinib","label-pemigatinib","label-futibatinib","smpc-balversa","smpc-pemazyre","smpc-lytgobi","kommalapati-2021","subbiah-2023"]},"variants":[{"name":"Erdafitinib (Balversa): US and EU dose rules","differs":"Phosphate at 14 to 21 days decides whether the dose rises from 8 mg to 9 mg (only if under 9.0 mg/dL), then monthly checks. Under 7 mg/dL: continue. 7 to 8.99 mg/dL (2.25 to 2.90 mmol/L): continue, start a binder, and reduce the dose if it stays at 7 mg/dL or more for 2 months. 9 to 10 mg/dL (2.91 to 3.20 mmol/L): withhold with weekly checks until under 7 mg/dL, restart at the same dose, and reduce if it stays at 9 mg/dL or more for 1 month. Above 10 mg/dL: withhold with weekly checks until under 7 mg/dL, then restart at the first reduced dose (the US text says \"may restart\"), and stop for good if 10 mg/dL or more lasts over 2 weeks. The US text restricts phosphate to 600 to 800 mg a day in all patients; the EU text does so from 5.5 mg/dL (1.75 mmol/L), says a non-calcium binder such as sevelamer carbonate should be considered for persistent rises, advises against vitamin D supplements, and stops the drug for good for a significant change in kidney function or grade 3 hypocalcaemia due to hyperphosphataemia.","evidence":"Regulatory texts. Raised phosphate in 73% of 479 patients (US pooled safety population), median onset 16 days; 24% took binders; vascular calcification in 0.2%. The EU text reports hyperphosphataemia as an adverse event in 78.5% and hypophosphataemia in 5.6%.","sources":["label-erdafitinib","smpc-balversa"]},{"name":"Pemigatinib (Pemazyre) dose rules","differs":"Low-phosphate diet above 5.5 mg/dL. Above 7 and up to 10 mg/dL: start phosphate-lowering therapy and check weekly; withhold if not under 7 mg/dL within 2 weeks of starting it; restart at the same dose the first time and a lower dose for later recurrences. Above 10 mg/dL: phosphate-lowering therapy and weekly checks; withhold if not 10 mg/dL or less within 1 week; restart at the next lower dose when under 7 mg/dL; stop for good if it recurs above 10 mg/dL after 2 dose reductions.","evidence":"US prescribing information: hyperphosphataemia by laboratory value in 93% of 635 patients, median onset 8 days, phosphate-lowering therapy in 33%. The EU text gives the same thresholds, says in its posology text that adding phosphate-lowering therapy above 7 mg/dL \"should be considered\", and adds closer follow-up of bone mineralisation in people with high or low phosphate.","sources":["label-pemigatinib","smpc-pemazyre"]},{"name":"Futibatinib (Lytgobi) dose rules","differs":"Diet and phosphate-lowering therapy from 5.5 mg/dL, with weekly checks. Above 7 and up to 10 mg/dL: reduce to the next lower dose rather than withhold; reduce again if not 7 mg/dL or less within 2 weeks; withhold only if still not controlled 2 weeks after the second reduction. Above 10 mg/dL: withhold until 7 mg/dL or less and restart at the next lower dose; stop for good if not 7 mg/dL or less within 2 weeks after 2 interruptions and reductions.","evidence":"US prescribing information: hyperphosphataemia in 88% of 318 patients, median onset 5 days, binders in 77%. In the manufacturer's pooled analysis of 469 patients (supported by Taiho Oncology) hyperphosphataemia occurred in 82.1%, was grade 3 or higher in 18.8% by the trial's own phosphate-based grading, and was the commonest reason for dose modification (23.5%).","sources":["label-futibatinib","smpc-lytgobi","meric-bernstam-2024"]},{"name":"Choice of phosphate binder","differs":"Non-calcium binder such as sevelamer carbonate (EU erdafitinib text); lanthanum or calcium-based binders rather than sevelamer, magnesium-based binders or sucroferric oxyhydroxide when the person has diarrhoea, and lanthanum rather than calcium when calcium is high or vascular calcification is a risk (Kommalapati 2021); calcium carbonate \"may be used\" when calcium is normal and sevelamer is preferred when it is raised (Subbiah 2023).","evidence":"Opinion in each case; Kommalapati 2021 says most of the data on binders come from kidney medicine, and none of the three sources cites a trial comparing binders in people on FGFR inhibitors. Kommalapati 2021 had no external funding; Subbiah 2023 was sponsored by Incyte.","sources":["smpc-balversa","kommalapati-2021","subbiah-2023"]},{"name":"Acetazolamide added to a binder","differs":"Acetazolamide, which the review classes as a phosphaturic agent (one that increases phosphate elimination), can be considered after the binder dose has been raised. The review's table gives a starting dose of 250 mg once a day and a maximum of 250 mg two or three times a day, and pairs it with the maximum binder dose at 7 mg/dL or more. The review says it is contraindicated in advanced liver dysfunction and should be avoided with extensive liver metastases or extensive intrahepatic cholangiocarcinoma with compromised liver function.","evidence":"Opinion in the Kommalapati review. Subbiah 2023 says only that it \"may also be used\"; in the Meric-Bernstam pooled analysis 26.4% of patients on futibatinib 20 mg took it. None of the six regulatory texts mentions it, and the papers read report no trial of it in this setting.","sources":["kommalapati-2021","subbiah-2023","meric-bernstam-2024"]},{"name":"Earlier dose reduction than the label (review algorithm)","differs":"Dietary advice once phosphate rises more than 25% above baseline in the first week; a binder considered at 5.5 to 6.9 mg/dL for any FGFR inhibitor; dose reduction considered once phosphate is 7 mg/dL or more on two occasions, or 10 mg/dL or more once, despite diet and binders.","evidence":"Kommalapati 2021, an unfunded narrative review, which says there is no optimal cut-off for dose reduction. It predates the futibatinib label and differs from all three labels.","sources":["kommalapati-2021"]}],"grades":[{"claim":"Phosphate restricted to 600 to 800 mg a day and phosphate-raising agents avoided (erdafitinib, US)","grade":"Regulatory label; not graded","source":"label-erdafitinib","quote":"Restrict dietary phosphate intake (600–800 mg daily) and avoid concomitant use of agents that may increase serum phosphate levels."},{"claim":"Erdafitinib stopped for good if phosphate of 10 mg/dL or more lasts over 2 weeks","grade":"Regulatory label; not graded","source":"label-erdafitinib","quote":"If hyperphosphatemia (≥10 mg/dL) for >2 weeks, discontinue BALVERSA permanently."},{"claim":"A non-calcium binder for persistently raised phosphate (erdafitinib, EU)","grade":"Regulatory product information; not graded","source":"smpc-balversa","quote":"adding a non-calcium containing phosphate binder (e.g., sevelamer carbonate) should be considered as needed"},{"claim":"Pemigatinib withheld if phosphate is not under 7 mg/dL within 2 weeks of a binder","grade":"Regulatory label; not graded","source":"label-pemigatinib","quote":"Withhold PEMAZYRE if levels are not < 7 mg/dL within 2 weeks of starting phosphate lowering therapy."},{"claim":"Futibatinib: diet and binder from 5.5 mg/dL","grade":"Regulatory label; not graded","source":"label-futibatinib","quote":"Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL."},{"claim":"Futibatinib: binder from 5.5 mg/dL (EU)","grade":"Regulatory product information; not graded","source":"smpc-lytgobi","quote":"A phosphate-lowering therapy should be initiated when serum phosphate level is ≥ 5.5 mg/dL."},{"claim":"Stop binders and diet if treatment stops or phosphate falls below normal (futibatinib, EU)","grade":"Regulatory product information; not graded","source":"smpc-lytgobi","quote":"If Lytgobi treatment is stopped or serum phosphate level falls below normal range, phosphate-lowering therapy and diet should be discontinued."},{"claim":"Closer follow-up of bone mineralisation with high or low phosphate (pemigatinib, EU)","grade":"Regulatory product information; not graded","source":"smpc-pemazyre","quote":"For patients presenting with hyperphosphataemia or hypophosphataemia, additional close monitoring and follow-up is recommended regarding dysregulation of bone mineralization."},{"claim":"Lanthanum and calcium-based binders preferred in people with diarrhoea","grade":"Narrative review, no external funding; not graded","source":"kommalapati-2021","quote":"In patients who also have FGFR-inhibitor-associated diarrhea, lanthanum and calcium-based regimens are preferred over magnesium-based regimens, sevelamer, and sucroferric oxyhydroxide as the latter can exacerbate the diarrhea caused by FGFR inhibitors."},{"claim":"Sevelamer when calcium is also raised, calcium carbonate otherwise","grade":"Narrative review sponsored by Incyte; not graded","source":"subbiah-2023","quote":"If a patient has hypercalcemia and hyperphosphatemia, then sevelamer is preferred. If a patient has only hyperphosphatemia with no elevation in calcium levels, then calcium carbonate may be used."},{"claim":"Binders started at the lowest possible dose","grade":"Narrative review sponsored by Incyte; not graded","source":"subbiah-2023","quote":"When initiating phosphate binders, the lowest possible dose should be used to mitigate development of hypophosphatemia."},{"claim":"No agreed phosphate cut-off for reducing the dose","grade":"Narrative review, no external funding; not graded","source":"kommalapati-2021","quote":"Though there is no optimal cut off phosphate values to consider a dose reduction of the FGFR inhibitor, dose reduction should be considered once the phosphate levels reach ≥7 mg/dL (on two separate occasions) or one episode of ≥10 mg/dL despite optimization of diet and phosphate binding agents."},{"claim":"Eye examinations monthly for 4 months then every 3 months (erdafitinib)","grade":"Regulatory label; not graded","source":"label-erdafitinib","quote":"Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms."}],"sources":[{"key":"label-erdafitinib","label":"Balversa (erdafitinib) tablets: US prescribing information, sections 2.2, 2.3, 5.1, 5.2 and 7","publisher":"Janssen, via DailyMed (US National Library of Medicine)","year":2025,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-pemigatinib","label":"Pemazyre (pemigatinib) tablets: US prescribing information, sections 2.3, 5.1 and 5.2","publisher":"Incyte, via DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-futibatinib","label":"Lytgobi (futibatinib) tablets: US prescribing information, sections 2.3, 5.1 and 5.2","publisher":"Taiho, via DailyMed (US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1332a1-0581-4707-9bf6-1eccfa39bef4","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-balversa","label":"Balversa: EU summary of product characteristics, sections 4.2 and 4.4 (the text served by the EMA on the day it was read)","publisher":"European Medicines Agency","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf","gradingScheme":"Regulatory product information; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-pemazyre","label":"Pemazyre: EU summary of product characteristics, sections 4.2 and 4.4 (the text served by the EMA on the day it was read)","publisher":"European Medicines Agency","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf","gradingScheme":"Regulatory product information; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-lytgobi","label":"Lytgobi: EU summary of product characteristics, sections 4.2 and 4.4 (the text served by the EMA on the day it was read)","publisher":"European Medicines Agency","year":2026,"url":"https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf","gradingScheme":"Regulatory product information; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"kommalapati-2021","label":"FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice","publisher":"Cancers (Kommalapati et al.); no external funding","year":2021,"url":"https://doi.org/10.3390/cancers13122968","doi":"10.3390/cancers13122968","gradingScheme":"Narrative review; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"subbiah-2023","label":"Clinical development and management of adverse events associated with FGFR inhibitors (sponsored by Incyte; medical writing funded by Incyte)","publisher":"Cell Reports Medicine (Subbiah and Verstovsek); sponsored by Incyte Corporation","year":2023,"url":"https://doi.org/10.1016/j.xcrm.2023.101204","doi":"10.1016/j.xcrm.2023.101204","gradingScheme":"Narrative review; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"meric-bernstam-2024","label":"Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients (supported by Taiho Oncology, which took part in the analysis and writing)","publisher":"Clinical Cancer Research (Meric-Bernstam et al.); supported by Taiho Oncology","year":2024,"url":"https://doi.org/10.1158/1078-0432.CCR-23-2646","doi":"10.1158/1078-0432.CCR-23-2646","gradingScheme":"Pooled trial safety analysis with recommendations based on investigators' clinical expertise; not graded.","read":"full-text","accessed":"2026-11-17"}],"upgrades":[],"gaps":["No ESMO, ASCO, MASCC or NCCN guideline on high phosphate from FGFR inhibitors was found. Outside the regulators' texts, the management advice is narrative review and expert opinion, most of it sponsored by a manufacturer.","No trial has compared phosphate binders, or tested acetazolamide, in people on FGFR inhibitors; the sources give three different first choices.","The US labels for pemigatinib and futibatinib say to monitor for hyperphosphataemia but give no schedule beyond weekly checks once it is raised; how often to test in the first weeks is left to the clinician.","Labels print thresholds in mg/dL. The mmol/L values here are those printed in the EU erdafitinib text (5.5 mg/dL as 1.75, 7.00 as 2.25, 9.00 as 2.91, 10.00 as 3.20 mmol/L); the EU pemigatinib and futibatinib texts print mg/dL only.","How much a low-phosphate diet achieves on its own in this setting has not been measured; the dietary advice is carried over from kidney disease. The review's examples of food swaps were read but are not reproduced here.","Whether a higher phosphate predicts a better response, and so whether aggressive lowering matters to cancer control, is debated in the papers found by title and was not assessed here.","Infigratinib is named in the reviews but no current DailyMed label was found for it, so no dose rule is given.","The eye step is a pointer only: the detailed eye rules (central serous retinopathy and retinal pigment epithelial detachment) differ by medicine and are in each label; no protocol here covers them yet.","The year given for the three EU product information documents is the year they were read; the texts print no date of revision.","On 17 November 2026 no source read was found to say which blood tests besides phosphate to take before starting, to name a dietitian, or to set a time limit for acting on cramps, tingling or skin lesions beyond telling patients to inform their team immediately; earlier wording on these points was removed.","The review papers suggest phosphate checks early in each cycle (Kommalapati 2021 gives day 4 and day 21 of a 4-week cycle); no label sets this."]},"route":"/protocols/hyperphosphataemia-on-fgfr-inhibitors/","neighbours":{"target":[{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"drug":[{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/"},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/"},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/"}],"pathway":[{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/"}],"protocol":[{"id":"low-potassium-and-low-phosphate-on-anticancer-drugs","kind":"protocol","name":"Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds","route":"/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/"},{"id":"retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors","kind":"protocol","name":"Retinal and visual side effects of FGFR, MEK and ALK inhibitors and other targeted drugs: eye examinations and dose rules","route":"/protocols/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors/"}]}}